Cottin, Vincent http://orcid.org/0000-0002-5591-0955
Martinez, Fernando J.
Jenkins, R. Gisli
Belperio, John A.
Kitamura, Hideya
Molina-Molina, Maria
Tschoepe, Inga
Coeck, Carl
Lievens, Dirk
Costabel, Ulrich
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
https://doi.org/10.1186/s12931-022-01974-2
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
https://doi.org/10.1136/bmj-2021-066354
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
https://doi.org/10.1136/bmjresp-2017-000212
Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
https://doi.org/10.1136/bmjresp-2021-001167
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
https://doi.org/10.1186/s12931-023-02371-z
P163 A multicentre retrospective cohort comparison of aetiology and survival in patients with chronic hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis
https://doi.org/10.1136/thorax-2018-212555.321
Funding for this research was provided by:
The INBUILD trial was funded by Boehringer Ingelheim.
Article History
Received: 22 November 2021
Accepted: 24 February 2022
First Online: 7 April 2022
Declarations
:
: The INBUILD trial was conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and was approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating center. All patients provided written informed consent before study entry.
: Not applicable.
: VC reports grants from Boehringer Ingelheim (BI); consulting and/or speaker fees from AstraZeneca, Bayer, Merck Sharp & Dohme, BI, Bristol-Myers Squibb (BMS), FibroGen, Galapagos, Novartis, Roche/Promedior, Sanofi, Shionogi; travel fees from BI and Roche/Promedior; and participation in a Data Safety and Monitoring Board for Celgene, Galapagos, Galecto and Roche/Promedior. FJM reports grants or contracts from Afferent/Merck, Bayer, Biogen, Nitto, Respivant, Roche, Veracyte for participation in Steering Committees of ILD studies; consulting fees from AbbVie, BI, BMS, Bridge Biotherapeutics, CSL Behring, DevPro, Genentech, IQVIA, Sanofi, Shionogi, twoXAR, Veracyte; honoraria for an internal presentation from United Therapeutics; and has participated on Data Safety Monitoring Boards or Advisory Boards for Biogen and BI. RGJ reports grants paid to his institution from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, Pliant, Redx; consulting fees from BMS, Daewoong Pharmaceuticals, Pliant, Redx, Resolution Therapeutics, Veracyte; honoraria for lectures from AstraZeneca, Chiesi, PatientMPower, Roche; has participated on Data Safety Monitoring Boards or Advisory Boards for BI, Galapagos, Vicore; and has held unpaid leadership or fiduciary roles for Action for Pulmonary Fibrosis and NuMedii. JAB, HK and MMM have nothing to report. IT is a contractor to BI. CC and DL are employees of BI. UC reports consulting fees from BI, Genentech, Pliant, Roche; lecture fees from AstraZeneca, BI, Novartis, Roche; support for attending meetings from BI, Roche; and has participated on Data Safety Monitoring Boards or Advisory Boards for BI, Galapagos, Roche.